檢索結果 - Amy Harker-Murray
- Showing 1 - 2 results of 2
-
1
-
2
Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial 由 Alain P. Algazi, Megan Othus, Adil Daud, Roger S. Lo, Janice M. Mehnert, Thach-Giao Truong, Robert M. Conry, Kari Kendra, Gary C. Doolittle, Joseph I. Clark, Michael J. Messino, Dennis F. Moore, Christopher D. Lao, Bryan A. Faller, Rangaswamy Govindarajan, Amy Harker-Murray, Luke Dreisbach, James Moon, Kenneth F. Grossmann, Antoni Ribas
出版 2020Artigo
相關主題
Biology
Cancer
Chemotherapy
Internal medicine
Medicine
Oncology
Randomized controlled trial
Breast cancer
Cancer research
Cell biology
Clinical trial
Dabrafenib
Dosing
Kinase
MAPK/ERK pathway
MEK inhibitor
Melanoma
Metastatic melanoma
Neoadjuvant therapy
Paleontology
Progression-free survival
Randomization
Stage (stratigraphy)
Surgery
Trametinib
Urology
Vemurafenib